Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?

Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49. doi: 10.1007/s00270-010-0012-y. Epub 2010 Nov 12.


Conventional transcatheter arterial chemoembolization and chemoembolization with drug-eluting beads are increasingly being performed interchangeably in many institutions throughout the world. As both therapies continue to being tested in many phase II and III studies and in combination with other therapies, especially targeted agents, for treatment of primary and metastatic liver cancer, it is imperative to review their current status and evaluate their impact on patient survival. This review critically assesses patient selection, indications, contraindications, techniques, materials, safety, and clinical outcomes of patients treated with conventional chemoembolization and chemoembolization with drug-eluting beads.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemoembolization, Therapeutic / methods*
  • Contraindications
  • Drug Delivery Systems
  • Humans
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Microspheres*
  • Outcome and Process Assessment, Health Care
  • Patient Selection
  • Radiography, Interventional / methods*


  • Antineoplastic Agents